Aptorum Group Limited products

A repurposed small molecule drug discovered from our SMART-ACT® platform, which has the potential to help develop drugs with well-established safety profiles in a time- and cost-effective manner

Staphylococcus aureus are gram-positive bacteria and the leading cause of skin and soft tissue infections, but can cause serious infections such as pneumonia, bacteraemia, and bone infections. Vancomycin is the most frequently prescribed treatment for methicillin-resistant Staphylococcus aureus (MRSA); however, vancomycin has been >60 years in use and has been shown to have slow bactericidal activity, poor anti-staphylococcal activity, poor tissue penetration, high rates of infection relapse, and can cause resistance (vancomycin-intermediate (VISA) and vancomycin-resistant (VRSA)). MRSA (pneumonia) mortality rate is between 30% - 55.5%, MRSA (skin and soft tissue) recurrence rate is approximately 70%, New efficacious and safe therapeutics are urgently needed